Pharmacological effects and clinical evaluation of zilucoplan for generalized myasthenia gravis

VernacularTitle:治疗成人重症肌无力新药zilucoplan的药理作用与临床评价
Author: Lu CHENG ¹ ; Ran XIE ; Nan ZHAO ; Bo JIA ; Xia ZHAO
Author Information

1. 北京大学第一医院药物临床试验机构,北京 100009
Keywords: zilucoplan; inhibitor of complement component 5; generalized myasthenia gravis; clinical evaluation; safety
From: The Chinese Journal of Clinical Pharmacology 2024;40(9):1368-1371
CountryChina
Language:Chinese
Abstract: Zilucoplan is a novel subcutaneous self-administered macrocyclic peptide inhibitor of complement component 5.It was approved by the FDA in October 2023 for the treatment of adults with generalized myasthenia gravis(gMG)who are positive for acetylcholine receptor(AChR)antibodies.This article reviews its pharmacological action,pharmacokinetics,clinical evaluation and safety.